Kostyuk, AAlmadiyeva, ANurgozhin, T2017-12-202017-12-202017-10-01A Kostyuk, A Almadiyeva, T Nurgozhin, PCV81 - Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective, In Value in Health, Volume 20, Issue 9, 2017, Page A61510983015https://www.sciencedirect.com/science/article/pii/S1098301517315619http://nur.nu.edu.kz/handle/123456789/2963Apixaban, dabigatran, and rivaroxaban are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). Although warfarin remains the standard of care in Kazakhstan.The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in KazakhstanenArticleCopyright © 2017 Published by Elsevier Inc.